Boston Scientific Recalls Hundreds of Thousands After FDA Software Flag
Boston Scientific is recalling hundreds of thousands of devices after the FDA flagged a software issue, alongside a cluster of Class II recalls tied to the TheraSphere 360 platform. The action follows recent earnings and guidance updates and shifts focus toward execution and product-quality risk, with investors weighing the reported US$5,442m of Q2 2026 sales and related disclosures.